BONEX.ST
BONEX.ST
SE0009858152
BONESUPPORT HOLDING AB
Loading chart...

Company Profile

Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally. The company offers CERAMENT Bone Void Filler, an injectable ceramic bone graft substitute that remodels to host bone; CERAMENT G, an injectable ceramic bone graft substitute that remodels to host bone and elutes Gentamicin during the critical first 30 days of bone healing, as well as treats and prevents bone infection; and CERAMENT V, an injectable ceramic bone graft substitute that remodels to host bone and elutes Vancomycin during the critical first 30 days of bone healing, as well as treats and prevents bone infection. It also provides CERAMENT Bead Tray, an adjunctive local delivery option for surgeons desiring targeted delivery to osseous defects and for dead space management. Bonesupport Holding AB (publ) was founded in 1999 and is headquartered in Lund, Sweden.

Related stocks

SYNSAM.ST
SYNSAM.ST • Sweden
Synsam AB
51.7 SEK
727.36M USD 1Y -12.9%
DYVOX.ST
DYVOX.ST • Sweden
Dynavox Group AB
82.8 SEK
878.75M USD 1Y -24.8%
SKAN.SW
SKAN.SW • Switzerland
SKAN N
70.7 CHF
1.92B USD 1Y +22.5%
OBCK.DE
OBCK.DE • Germany
Ottobock SE & Co. KGaA I
53.2 EUR
3.81B USD
ALIF-B.ST
ALIF-B.ST • Sweden
AddLife AB ser. B
169 SEK
2.06B USD 1Y -9.1%
FIE.DE
FIE.DE • Germany
Fielmann Group AG I
37.35 EUR
3.51B USD 1Y -25.6%
AMS.L
AMS.L • United Kingdom
ADVANCED MEDICAL SOLUTIONS GROU
282 GBp
812.43M USD 1Y +24.4%
SFL.MI
SFL.MI • Italy
SAFILO GROUP
1.85 EUR
806.23M USD 1Y +4.9%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
50.1% p.a.
Max Drawdown (5Y)
-58.0%
Sharpe Ratio (5Y)
0.79
Beta Factor
0.31
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 73.9 (Elevated multiple compression risk)
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (50.1% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -71.0% in the extended horizon.
ende